Annual Report for FY 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vanta Bioscience, a preclinical contract research organization listed on BSE SME, filed its 9th Annual Report for FY 2024-25. Standalone revenue from operations collapsed to Rs. 11.27 lakh from Rs. 85.58 lakh in the previous year, an ~87% decline. The company swung from a small profit of Rs. 5.11 lakh in FY24 to a standalone loss after tax of Rs. 2.66 crore (EPS of Rs. -4.21). On a consolidated basis, revenue fell to Rs. 20.74 lakh from Rs. 98.29 lakh and the loss widened to Rs. 4.77 crore. The board attributed the poor performance to liquidity issues and the lingering negative impact of past CIRP/NCLT proceedings, which also caused the loss of experienced employees. No dividend was recommended.
Sharp revenue collapse and a swing to losses raise serious red flags for shareholders. Going concern concerns at the subsidiary level, delayed statutory payments, and continued reliance on promoter loans point to weak financial health and likely pressure on the stock price.